4.5 Article

New Class of Adjuvants Enables Lower Dosing of Colistin Against Acinetobacter baumannii

Journal

ACS INFECTIOUS DISEASES
Volume 4, Issue 9, Pages 1368-1376

Publisher

AMER CHEMICAL SOC
DOI: 10.1021/acsinfecdis.8b00103

Keywords

antibiotic resistance; Acinetobacter baumannii; antibiotic adjuvant; colistin

Funding

  1. National Institutes of Health [GM05579]

Ask authors/readers for more resources

Antibiotic resistance has become increasingly prevalent over the past few decades, and this combined with a dearth in the development of new classes of antibiotics to treat multidrug resistant Gram-negative infections has led to a significant global health problem and the increased usage of colistin as the last resort antibiotic. Colistin, however, presents dose dependent toxicity in the clinic. One potential approach to combatting this problem is the use of an antibiotic adjuvant, a compound that is nontoxic to the bacteria that enhances the potency of colistin and ultimately allows for reducing dosing. Herein, we present a new urea-containing class of 2-aminoimidazole-based adjuvants that potentiates colistin activity against colistin-sensitive Acinetobacter baumannii. Lead compounds enabled 1000-fold reduction in the minimum inhibitory concentration of colistin in vitro and showed efficacy in a Galleria mellonella infection model, representing the first step toward validating the potential of employing these adjuvants to lower colistin dosage.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.5
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available